Zobrazeno 1 - 10 of 188 pro vyhledávání: '"BF Hansen"'
1
Short hard palate in prenatal trisomy 21
Autor: H Lauridsen, BF Hansen, I Reintoft, Lene Theil Skovgaard, I Kjær, Jean W. Keeling
Publikováno v: Orthodontics & Craniofacial Research. 8:91-95
Structured Abstract Authors – Lauridsen H, Hansen BF, Reintoft I, Keeling JW, Skovgaard LT, Kjaer I Objective – The aim of the present study was for the first time to examine on postmortal material the total midpalatal length of the hard palate a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::485799ffd71162edbafb4afd3d7517a0
https://doi.org/10.1111/j.1601-6343.2005.00318.x
Zobrazit plný text záznamu
2
Hydatidiform mole and fetus with normal karyotype: support of a separate entity
Autor: Lo, Vejerslev, Lone Sunde, Bf, Hansen, Jk, Larsen, Ij, Christensen, Larsen G
Publikováno v: Europe PubMed Central
Repetitive hydatidiform mole was observed in four pregnancies. The pregnancies presented with heavy bleeding and vomiting, but the post-evacuation courses were uncomplicated, with rapid regression of serum hCG levels. Cytogenetic investigations, anal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::39d35388475b131367be40e5e2094d6c
https://pubmed.ncbi.nlm.nih.gov/2030859
Zobrazit plný text záznamu
4
Akademický článek
Glucose-sensitive insulin with attenuation of hypoglycaemia.
Autor: Hoeg-Jensen T; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Kruse T; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Brand CL; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Sturis J; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Fledelius C; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Nielsen PK; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Nishimura E; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Madsen AR; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Lykke L; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Halskov KS; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Koščová S; APIGENEX, Prague, Czech Republic., Kotek V; APIGENEX, Prague, Czech Republic., Davis AP; University of Bristol, Bristol, UK., Tromans RA; Carbometrics, Bristol, UK., Tomsett M; Carbometrics, Bristol, UK., Peñuelas-Haro G; Carbometrics, Bristol, UK., Leonard DJ; Carbometrics, Bristol, UK., Orchard MG; Carbometrics, Bristol, UK., Chapman A; Carbometrics, Bristol, UK., Invernizzi G; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Johansson E; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Granata D; Digital Science and Innovation, Novo Nordisk, Bagsværd, Denmark., Hansen BF; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Pedersen TA; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Kildegaard J; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Pedersen KM; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Refsgaard HHF; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Alifrangis L; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Fels JJ; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Neutzsky-Wulff AV; Global Research Technologies, Novo Nordisk, Bagsværd, Denmark., Sauerberg P; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark., Slaaby R; Global Drug Discovery, Novo Nordisk, Bagsværd, Denmark. risl@novonordisk.com.
Publikováno v: Nature [Nature] 2024 Oct; Vol. 634 (8035), pp. 944-951. Date of Electronic Publication: 2024 Oct 16.
Zobrazit plný text záznamu
5
Akademický článek
Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models.
Autor: Hvid H; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Brand CL; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Hummelshøj T; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Jensen S; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Bouman SD; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Bowler A; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark.; QC Laboratories, Syntese A/S, Hvidovre, Denmark., Poulsen BR; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Tiainen P; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Åkertröm T; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Demozay D; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Hoeg-Jensen T; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Ingvorsen C; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Pedersen TÅ; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., McGuire J; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark.; Catalyst Biosciences, San Francisco, CA, USA., Egebjerg T; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Cappelen KA; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Eliasen IP; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Hansen BF; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Hennen S; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark.; Grünethal GmbH, Aachen, Germany., Stidsen CE; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Olsen GS; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Roed NK; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark. NIKU@novonordisk.com.
Publikováno v: Diabetologia [Diabetologia] 2023 Feb; Vol. 66 (2), pp. 376-389. Date of Electronic Publication: 2022 Nov 21.
Zobrazit plný text záznamu
6
Akademický článek
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.
Autor: Nishimura E; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark enis@novonordisk.com., Pridal L; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Glendorf T; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Hansen BF; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Hubálek F; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Kjeldsen T; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Kristensen NR; Development, Novo Nordisk A/S, Søborg, Denmark., Lützen A; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Lyby K; Development, Novo Nordisk A/S, Søborg, Denmark., Madsen P; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Pedersen TÅ; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Ribel-Madsen R; Development, Novo Nordisk A/S, Søborg, Denmark., Stidsen CE; Research & Early Development, Novo Nordisk A/S, Måløv, Denmark., Haahr H; Development, Novo Nordisk A/S, Søborg, Denmark.
Publikováno v: BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2021 Aug; Vol. 9 (1).
Zobrazit plný text záznamu
7
Author Correction: Molecular engineering of safe and efficacious oral basal insulin.
Autor: Hubálek F; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Refsgaard HHF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Gram-Nielsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Madsen P; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nishimura E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Münzel M; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Brand CL; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Stidsen CE; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Claussen CH; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Wulff EM; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Pridal L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ribel U; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Kildegaard J; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Porsgaard T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Johansson E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Steensgaard DB; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hovgaard L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Glendorf T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hansen BF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Jensen MK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nielsen PK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ludvigsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Rugh S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Garibay PW; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Moore MC; Vanderbilt University, Nashville, TN, USA., Cherrington AD; Vanderbilt University, Nashville, TN, USA., Kjeldsen T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark. ThK@novonordisk.com.
Publikováno v: Nature communications [Nat Commun] 2020 Aug 20; Vol. 11 (1), pp. 4232. Date of Electronic Publication: 2020 Aug 20.
Zobrazit plný text záznamu
8
Akademický článek
Molecular engineering of safe and efficacious oral basal insulin.
Autor: Hubálek F; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Refsgaard HHF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Gram-Nielsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Madsen P; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nishimura E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Münzel M; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Brand CL; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Stidsen CE; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Claussen CH; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Wulff EM; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Pridal L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ribel U; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Kildegaard J; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Porsgaard T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Johansson E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Steensgaard DB; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hovgaard L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Glendorf T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hansen BF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Jensen MK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nielsen PK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ludvigsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Rugh S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Garibay PW; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Moore MC; Vanderbilt University, Nashville, TN, USA., Cherrington AD; Vanderbilt University, Nashville, TN, USA., Kjeldsen T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark. ThK@novonordisk.com.
Publikováno v: Nature communications [Nat Commun] 2020 Jul 27; Vol. 11 (1), pp. 3746. Date of Electronic Publication: 2020 Jul 27.
Zobrazit plný text záznamu
9
Akademický článek
Increased insulin receptor binding and increased IGF-1 receptor binding are linked with increased growth of L6hIR cell xenografts in vivo.
Autor: Hvid H; Global Drug Discovery, Novo Nordisk A/S, Copenhagen, Denmark. hhvd@novonordisk.com., Glendorf T; Global Drug Discovery, Novo Nordisk A/S, Copenhagen, Denmark., Brandt J; Global Research Technologies, Novo Nordisk A/S, Copenhagen, Denmark., Slaaby R; Global Drug Discovery, Novo Nordisk A/S, Copenhagen, Denmark., Lützen A; Global Drug Discovery, Novo Nordisk A/S, Copenhagen, Denmark., Kristensen K; Global Drug Discovery, Novo Nordisk A/S, Copenhagen, Denmark., Hansen BF; Global Drug Discovery, Novo Nordisk A/S, Copenhagen, Denmark.
Publikováno v: Scientific reports [Sci Rep] 2020 Apr 29; Vol. 10 (1), pp. 7247. Date of Electronic Publication: 2020 Apr 29.
Zobrazit plný text záznamu
10
Akademický článek
Intraintestinal and Parenteral Administration of an Insulin Analogue Leads to Comparable Activation of Signaling Downstream of the Insulin Receptor in the Small Intestine.
Autor: Hvid H; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Kildegaard J; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Kristensen K; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Porsgaard T; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Jørgensen MS; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Ballarín-González B; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Ahnfelt-Rønne J; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Hansen BF; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., Nishimura E; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Publikováno v: Journal of diabetes science and technology [J Diabetes Sci Technol] 2020 Jan; Vol. 14 (1), pp. 112-119. Date of Electronic Publication: 2019 Jun 12.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje